Insulin pump therapy (continuous subcutaneous insulin infusion, CSII) is a form of intensified insulin treatment involving subcutaneous infusion of short-acting insulin from a portable pump. There is a well-established evidence base for the effectiveness of CSII in type 1 diabetes, which includes reduction in HbA1c, blood glucose variability, and all grades of hypoglycemia compared to MDI, but more research is needed on how new long-acting insulin preparations and more effective diabetes education will reduce the number who do not achieve target levels of control on MDI and who are thus candidates for CSII. Insulin pump therapy is an affordable, cost-effective therapeutic option for most healthcare settings. There is an increasing role for CSII in patients with poorly controlled type 2 diabetes who are not adequately managed on MDI, but smaller, cheaper, and simpler “patch” pumps are likely to be needed to make insulin pump therapy cost-effective in this type of diabetes.
KeywordsInsulin pump therapy Continuous subcutaneous insulin infusion CSII Type 1 diabetes Type 2 diabetes Hypoglycemia Glycemic control Intensified insulin therapy
- Grunberger G, Abelseth J, Bailey T, Bode B, Handelsman Y, Hellman R, Jovanovič L, Lane W, Raskin P, Tamborlane W, Rothermel C. Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force. Endocr Pract. 2014;20:463–89.CrossRefGoogle Scholar
- Laimer M, Melmer A, Mader JK, Schütz-Fuhrmann I, Engels H-R, Götz G, Pfeifer M, Hermann JM, Stettler C, Holl RW. Variability of basal rate profiles in insulin pump therapy and association with complications in type 1 diabetes mellitus. PLoS One. 2016;11(3):e0150604. https://doi.org/10.1371/journal.pone.0150604.CrossRefPubMedPubMedCentralGoogle Scholar
- Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010;(1):Art. No.: CD005103. https://doi.org/10.1002/14651858.CD005103.pub2.
- National Institute for Health and Care Excellence. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus. In: Technology appraisal guidance 151 (review of technology appraisal guidance 57). London, UK: NICE; 2008.Google Scholar
- Pickup JC, Kidd J, Burmiston S, Yemane N. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabet Metab Res Rev. 2006;22:232–7.CrossRefGoogle Scholar
- Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26:2598–603.CrossRefGoogle Scholar
- Sherr JL, Hermann JM, Campbell F, Foster NC, Hofer SE, Allgrove J, Maahs DM, Kapellen TM, Holman N, Tamborlane WV, Holl RW, Beck RW, Warner JT, T1D Exchange Clinic Network, DPV Initiative, National Paediatric Diabetes Audit, Royal College of Paediatrics and Child Health registries. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016;59:87–91.CrossRefGoogle Scholar
- Steineck I, Cederholm J, Eliasson B, Rawshani A, Eeg-Olofsson K, Svensson A-M, Zethelius B, Avdic T, Landin-Olsson M, Jendle J, Gudbjörnsdóttir S, the Swedish National Diabetes Register. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ. 2015;350:h3234.CrossRefGoogle Scholar